Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Ho K, Fleseriu M, Kaiser U, Salvatori R, Brue T, Lopes MB, Kunz P, Molitch M, Camper SA, Gadelha M, Syro L, Laws E, Reincke M, Nishioka H, Grossman A, Barkan A, Casanueva F, Wass J, Mamelak A, Katznelson L, Van Der Lely AJ, Radovick S, Bidlingmaier M, Boguszewski M, Bollerslev J, Hoffman AR, Oyesiku N, Raverot G, Ben-Shlomo A, Fowkes R, Shimon I, Fukuoka H, Pereira AM, Greenman Y, Heaney AP, Gurnell M, Johannsson G, Osamura RY, Buchfelder M, Zatelli MC, Korbonits M, Chanson P, Biermasz N, Clemmons DR, Karavitaki N, Bronstein MD, Trainer P, Melmed S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 5

Journal Issue: 3

DOI: 10.1210/jendso/bvaa205

Abstract

The WHO Classification of Endocrine Tumours designates pituitary neoplasms as adenomas. A proposed nomenclature change to pituitary neuroendocrine tumors (PitNETs) has been met with concern by some stakeholder groups. The Pituitary Society coordinated the Pituitary Neoplasm Nomenclature (PANOMEN) workshop to address the topic. Experts in pituitary developmental biology, pathology, neurosurgery, endocrinology, and oncology, including representatives nominated by the Endocrine Society, European Society of Endocrinology, European Neuroendocrine Association, Growth Hormone Research Society, and International Society of Pituitary Surgeons. Clinical epidemiology, disease phenotype, management, and prognosis of pituitary adenomas differ from that of most NETs. The vast majority of pituitary adenomas are benign and do not adversely impact life expectancy. A nomenclature change to PitNET does not address the main challenge of prognostic prediction, assigns an uncertain malignancy designation to benign pituitary adenomas, and may adversely affect patients. Due to pandemic restrictions, the workshop was conducted virtually, with audiovisual lectures and written precis on each topic provided to all participants. Feedback was collated and summarized by Content Chairs and discussed during a virtual writing meeting moderated by Session Chairs, which yielded an evidence-based draft document sent to all participants for review and approval. There is not yet a case for adopting the PitNET nomenclature. The PANOMEN Workshop recommends that the term adenoma be retained and that the topic be revisited as new evidence on pituitary neoplasm biology emerges.

Authors with CRIS profile

Involved external institutions

University of North Carolina at Chapel Hill United States (USA) (US) Cedars-Sinai Medical Center United States (USA) (US) University of California Los Angeles (UCLA) United States (USA) (US) Tel Aviv University Israel (IL) Johns Hopkins University (JHU) United States (USA) (US) University of Oslo Norway (NO) Oregon Health and Science University (OSHU) United States (USA) (US) Ludwig-Maximilians-Universität (LMU) Germany (DE) Northwestern University United States (USA) (US) Hospital Pablo Tobon Uribe Colombia (CO) University of Cambridge United Kingdom (GB) Emory University United States (USA) (US) University of Michigan United States (USA) (US) Leiden University Medical Center Netherlands (NL) Universidade Federal do Paraná (UFPR) Brazil (BR) University of Manchester United Kingdom (GB) École Polytechnique - Université Paris-Saclay France (FR) Stanford University United States (USA) (US) Universidade de Santiago Compostela (USC) Spain (ES) Rabin Medical Center / מרכז רפואי רבין‎‎ Israel (IL) Erasmus University Medical Center (MC) Netherlands (NL) Hospices Civils de Lyon (CHU) France (FR) Brigham and Women's Hospital (BWH) United States (USA) (US) Toranomon Hospital Japan (JP) Queen Mary University of London United Kingdom (GB) Yale University United States (USA) (US) Aix-Marseille University / Aix-Marseille Université France (FR) University of São Paulo / Universidade de São Paulo (USP) Brazil (BR) Garvan Institute of Medical Research Australia (AU) Università degli Studi di Ferrara Italy (IT) University College London (UCL) United Kingdom (GB) University of Birmingham United Kingdom (GB) Oxford University Hospitals NHS Foundation Trust United Kingdom (GB) Keio University / 慶應義塾大学 Japan (JP) University of Gothenburg / Göteborgs universitet Sweden (SE) Rutgers, The State University of New Jersey United States (USA) (US) Kobe University / 神戸大学 Japan (JP) Universidade Federal do Rio de Janeiro (UFRJ) / Federal University of Rio de Janeiro Brazil (BR) University of Virginia (UVA) United States (USA) (US) University of Oxford United Kingdom (GB)

How to cite

APA:

Ho, K., Fleseriu, M., Kaiser, U., Salvatori, R., Brue, T., Lopes, M.B.,... Melmed, S. (2021). Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time? Journal of the Endocrine Society, 5(3). https://doi.org/10.1210/jendso/bvaa205

MLA:

Ho, Ken, et al. "Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?" Journal of the Endocrine Society 5.3 (2021).

BibTeX: Download